Ledraxen (Enoxaparin Sodium)

Enoxaparin sodium binds to antithrombin III, markedly increasing its ability to inhibit clotting factors Xa and IIa. This selective inhibition reduces thrombin generation and fibrin clot formation, providing effective anticoagulation while preserving some clotting activity.

The dose of Ledraxen is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical scenario. Dosing regimens are individualized and should follow local therapeutic guidelines.

Ledraxen is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used in pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding, so clinical judgement is required.

To order Ledraxen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Compared with unfractionated heparin, enoxaparin (Ledraxen) offers more predictable pharmacokinetics, a longer half‑life, and does not require routine laboratory monitoring in most patients. It also has a lower incidence of heparin‑induced thrombocytopenia, though dosing adjustments are needed in severe renal impairment.

Ledraxen should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not store at room temperature for extended periods.

Ledraxen is administered by subcutaneous injection or intravenous infusion, depending on the clinical indication. The injection site is typically the abdomen or thigh, and aseptic technique must be observed. Intravenous administration is performed by a qualified healthcare professional using an appropriate infusion set.

The most serious risks include major bleeding (intracranial, gastrointestinal, or surgical site hemorrhage), severe thrombocytopenia, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of bleeding, sudden drop in platelet count, or hypersensitivity during therapy.

Ledraxen is contraindicated in patients with active major bleeding, known hypersensitivity to enoxaparin or other LMWHs, and in those with severe uncontrolled hypertension. Caution is also advised for individuals with a history of heparin‑induced thrombocytopenia, spinal or epidural anesthesia without appropriate precautions, and severe renal impairment.